Valuation: Filana Therapeutics, Inc.

Market Cap 46.58M 40.82M 37.89M 34.82M 65.61M 4.5B 66.58M 451M 177M 2.2B 175M 171M 7.6B P/E 2026 *
-1.02x
P/E 2027 * -0.81x
Enterprise Value 46.58M 40.82M 37.89M 34.82M 65.61M 4.5B 66.58M 451M 177M 2.2B 175M 171M 7.6B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.95%
Yield 2026 *
-
Yield 2027 * -
1 day-4.52%
1 week-12.34%
Current month-18.97%
1 month-22.23%
3 months-42.94%
6 months-58.44%
Current year-51.30%
1 week 0.96
Extreme 0.9556
1.09
1 month 0.96
Extreme 0.9556
1.37
Current year 0.96
Extreme 0.9556
2.49
1 year 0.96
Extreme 0.9556
4.98
3 years 0.96
Extreme 0.9556
42.2
5 years 0.96
Extreme 0.9556
146.16
10 years 0.76
Extreme 0.76
146.16
Manager TitleAgeSince
Chief Executive Officer 67 06/09/2024
Director of Finance/CFO 57 01/10/2018
Chief Tech/Sci/R&D Officer 70 07/08/2025
Director TitleAgeSince
Director/Board Member 78 07/12/2007
Chairman 67 17/07/2024
Chairman 74 09/09/2024
Date Insider Type Main position Quantity % Market Cap.
24/11/25 Buy

Director

8,600 0.0178%
20/11/25 Buy

Chief Executive Officer

150,000 0.3105%
19/11/25 Buy

Chief Executive Officer

73,385 0.1519%
Change 5-day change 1-year change 3-year change Capi.($)
-4.52%-12.34%-62.62%-95.54% 46.58M
-0.43%-4.26%+52.09%+85.69% 55.27B
+4.35%+5.49%+62.01%+65.25% 54.15B
-1.82%-2.89%+3.61%+405.88% 23.11B
-0.54%-0.17%-17.60%-15.43% 23.22B
+0.72%-0.25%+36.42%-3.28% 20.33B
-1.73%-0.58%+29.67%-30.23% 17.91B
+0.29%-0.86%+38.13%+549.12% 15.76B
+0.43%-10.61%+175.63%+299.61% 15B
-2.03%-1.03%+23.63%+179.23% 13.82B
Average -0.51%-2.72%+34.10%+144.03% 23.86B
Weighted average by Cap. +0.53%-1.05%+45.02%+135.38%

Financials

2026 *2027 *
Net sales - -
Net income -48.43M -42.43M -39.39M -36.2M -68.21M -4.67B -69.22M -469M -184M -2.29B -182M -178M -7.9B -60M -52.57M -48.81M -44.85M -84.51M -5.79B -85.75M -581M -228M -2.83B -225M -220M -9.79B
Net Debt - -
Logo Filana Therapeutics, Inc.
Filana Therapeutics, Inc., formerly Cassava Sciences, Inc., is a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, is an early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
Employees
19
Date Price Change Volume
22/07/26 $0.9643 -4.52% 487,060
21/07/26 $1.010 -0.98% 281,360
20/07/26 $1.020 -3.77% 413,271
17/07/26 $1.060 -1.85% 164,796
16/07/26 $1.080 -1.82% 399,511
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.9643USD
Average target price
6.500USD
Spread / Average Target
+574.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FLNA Stock